All Stories

  1. Pulmonary Artery and Vein Morphology as an Imaging Biomarker for the Diagnosis of Pulmonary Hypertension

    Article • Diagnostics, February 2026, MDPI AG

    Horst Olschewski

  2. Non-invasive mPAP/VO2 slope as predictor of pulmonary exercise hemodynamics and outcome

    Article • ERJ Open Research, November 2025, European Respiratory Society (ERS)

    Horst Olschewski

  3. How It Really Happened‐the Development of Inhaled Iloprost for Pulmonary Arterial Hypertension

    Article • Pulmonary Circulation, October 2025, Wiley

    Horst Olschewski

  4. Late Onset Pulmonary Arterial Hypertension Associated With Features of Pulmonary Veno‐Occlusive Disease and Rare Heterozygous Variants of KDR and EIF2AK4

    Article • Pulmonary Circulation, October 2025, Wiley

    Horst Olschewski

  5. Risikostratifizierung und Behandlungsziele bei pulmonalarterieller Hypertonie

    Article • Pneumologie, October 2025, Thieme Publishing Group

    Horst Olschewski

  6. IDO‐1 Promotes Pulmonary Vascular Remodeling Via Kynurenine Pathway in Pulmonary Arterial Hypertension

    Article • Journal of the American Heart Association, August 2025, Wolters Kluwer Health

    Horst Olschewski

  7. Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis

    Article • American Review of Respiratory Disease, August 2025, American Thoracic Society

    Athiththan Yogeswaran, Horst Olschewski, Professor Yuriy M. Sirenko

  8. Detection of structural pulmonary changes with real-time high-fidelity analysis of expiratory CO2

    Article • Journal of Breath Research, August 2025, Institute of Physics Publishing

    Horst Olschewski

  9. Soluble Transferrin Receptor-1 in Pulmonary Hypertension Associated with COPD

    Article • Lung, July 2025, Springer Science + Business Media

    Horst Olschewski

  10. Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta‐Registry

    Article • Pulmonary Circulation, July 2025, Wiley

    Athiththan Yogeswaran, Horst Olschewski, Professor Yuriy M. Sirenko

  11. Significance of Pulmonary Vascular Dysfunction in Chronic Obstructive Pulmonary Disease

    Article • Pulmonary Circulation, July 2025, Wiley

    Horst Olschewski

  12. Lipid Ratios for Diagnosis and Prognosis of Pulmonary Hypertension

    Article • American Review of Respiratory Disease, July 2025, American Thoracic Society

    Horst Olschewski

  13. Pulmonary Vascular Disease and Pulmonary Exercise Hemodynamics in Patients With Sjögren's Syndrome – A Cross-Sectional Study

    Article • Archivos de Bronconeumología (English Edition), May 2025, Elsevier

    Horst Olschewski

  14. Pathogenic SMAD6 variants in patients with idiopathic and complex congenital heart disease associated pulmonary arterial hypertension

    Article • npj Genomic Medicine, March 2025, Springer Science + Business Media

    Horst Olschewski

  15. Prognostic Relevance of Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Arterial Pressure Ratio and Its Association With Exercise Hemodynamics in Patients With Normal or Mildly Elevated Resting Pulmonary Arterial Pressure

    Article • CHEST Journal, February 2025, Elsevier

    Horst Olschewski

  16. Association of Phosphodiesterase-5 Inhibitor Treatment With Improved Survival in Pulmonary Hypertension Associated With COPD in the Pulmonary Vascular Research Institute GoDeep Meta-Registry

    Article • CHEST Journal, January 2025, Elsevier

    Athiththan Yogeswaran, Horst Olschewski, Professor Yuriy M. Sirenko

  17. Prognostic relevance of Exercise Pulmonary Hypertension: Results of the multi-center PEX-NET Clinical Research Collaboration

    Article • European Respiratory Journal, November 2024, European Respiratory Society (ERS)

    Horst Olschewski

  18. Reply to: The limits of normal of pulmonary arterial wedge pressure

    Article • European Respiratory Journal, November 2024, European Respiratory Society (ERS)

    Horst Olschewski

  19. Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH‐CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative—group 3 pulmonary hypertension

    Article • Pulmonary Circulation, October 2024, Wiley

    Horst Olschewski

  20. Association of PH-Targeted Therapy and Survival in Precapillary PH with mPAP between 21 and 24 mmHg

    Article • ERJ Open Research, September 2024, European Respiratory Society (ERS)

    Horst Olschewski

  21. Clinical Response to Pulmonary Arterial Hypertension Treatment Does Not Depend on Pulmonary Arterial Wedge Pressure: A Meta-Analysis Using Individual Participant Data from Randomized Clinical Trials

    Article • American Review of Respiratory Disease, September 2024, American Thoracic Society

    Horst Olschewski

  22. Lung Fibrosis Is Linked to Increased Endothelial Cell Activation and Dysfunctional Vascular Barrier Integrity

    Article • American Journal of Respiratory Cell and Molecular Biology, September 2024, American Thoracic Society

    Horst Olschewski

  23. Severe pulmonary hypertension in chronic obstructive pulmonary disease – From clinical perspective to histological evidence

    Article • International Journal of Cardiology Congenital Heart Disease, September 2024, Elsevier

    Horst Olschewski

  24. Risk stratification and treatment goals in pulmonary arterial hypertension

    Article • European Respiratory Journal, August 2024, European Respiratory Society (ERS)

    Horst Olschewski

  25. Pulmonary arterial wedge pressure in healthy subjects: a meta-analysis

    Article • European Respiratory Journal, July 2024, European Respiratory Society (ERS)

    Horst Olschewski

  26. The prognostic relevance of exercise pulmonary hypertension in cardiac and pulmonary diseases

    Article • Current Opinion in Pulmonary Medicine, July 2024, Wolters Kluwer Health

    Horst Olschewski

  27. Expiratory Venous Volume and Arterial Tortuosity are Associated with Disease Severity and Mortality Risk in Patients with COPD: Results from COSYCONET

    Article • International Journal of Chronic Obstructive Pulmonary Disease, July 2024, Taylor & Francis

    Horst Olschewski

  28. Compartment-specific remodeling patterns in end-stage chronic obstructive pulmonary disease with and without severe pulmonary hypertension

    Article • The Journal of Heart and Lung Transplantation, July 2024, Elsevier

    Horst Olschewski

  29. The TREK‐1 potassium channel is a potential pharmacological target for vasorelaxation in pulmonary hypertension

    Article • British Journal of Pharmacology, May 2024, Wiley

    Horst Olschewski

  30. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era

    Article • Circulation, May 2024, Wolters Kluwer Health

    Horst Olschewski

  31. CT-derived lung vessel morphology correlates with prognostic markers in precapillary pulmonary hypertension

    Article • The Journal of Heart and Lung Transplantation, January 2024, Elsevier

    Horst Olschewski

  32. Long-term sildenafil therapy for pulmonary veno-occlusive disease in association with melphalan therapy for multiple myeloma: A case report

    Article • SAGE Open Medical Case Reports, January 2024, SAGE Publications

    Horst Olschewski

  33. Myocardial strain parameters in pulmonary hypertension are determined by changes in volumetric function rather than by hemodynamic alterations

    Article • European Journal of Radiology, January 2024, Elsevier

    Horst Olschewski

  34. Pulmonal veno-okklusive Erkrankung (PVOD)

    Article • January 2024, Thieme Publishing Group

    Horst Olschewski

  35. Pulmonale Hypertonie

    Article • January 2024, Thieme Publishing Group

    Horst Olschewski

  36. Let’s Talk About Respiratory Swings!

    Article • American Review of Respiratory Disease, December 2023, American Thoracic Society

    Horst Olschewski

  37. Physical Activity, Depression and Quality of Life in COPD – Results from the CLARA II Study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, November 2023, Taylor & Francis

    Horst Olschewski

  38. Pentastatin, a matrikine of the collagen IVα5, is a novel endogenous mediator of pulmonary endothelial dysfunction

    Article • AJP Cell Physiology, November 2023, American Physiological Society

    Horst Olschewski

  39. Die neue Definition und Klassifikation der pulmonalen Hypertonie

    Article • Pneumologie, November 2023, Thieme Publishing Group

    Horst Olschewski

  40. Basement membrane product, endostatin, as a link between inflammation, coagulation and vascular permeability in COVID-19 and non-COVID-19 acute respiratory distress syndrome

    Article • Frontiers in Immunology, May 2023, Frontiers

    Horst Olschewski

  41. Hypoxia-inducible factor-2 may define different scenarios of COPD development/progression

    Article • European Respiratory Review, January 2023, European Respiratory Society (ERS)

    Oleh Myronenko, Horst Olschewski

  42. Apelin-17 to diagnose idiopathic pulmonary arterial hypertension: A biomarker study

    Article • Frontiers in Physiology, January 2023, Frontiers

    Horst Olschewski

  43. Abnormal pulmonary hemodynamics during exercise is associated with exercise capacity in COPD

    Article • Respiratory Research, December 2022, Springer Science + Business Media

    Horst Olschewski

  44. Prognostic Value of Exercise as Compared to Resting Pulmonary Hemodynamics in Patients with Normal or Mildly Elevated Pulmonary Arterial Pressure

    Article • American Review of Respiratory Disease, December 2022, American Thoracic Society

    Horst Olschewski

  45. Updated definition of exercise pulmonary hypertension

    Article • Breathe, December 2022, European Respiratory Society (ERS)

    Horst Olschewski

  46. Single-cell transcriptomics reveals skewed cellular communication and phenotypic shift in pulmonary artery remodeling

    Article • JCI Insight, October 2022, American Society for Clinical Investigation

    Horst Olschewski

  47. Impairment of the NKT–STAT1–CXCL9 Axis Contributes to Vessel Fibrosis in Pulmonary Hypertension Caused by Lung Fibrosis

    Article • American Review of Respiratory Disease, October 2022, American Thoracic Society

    Horst Olschewski

  48. Pulmonary vascular disease and exercise hemodynamics in chronic liver disease

    Article • Respiratory Medicine, October 2022, Elsevier

    Horst Olschewski

  49. Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis

    Article • Pharmacology & Therapeutics, September 2022, Elsevier

    Horst Olschewski

  50. Left atrial acceleration factor as a magnetic resonance 4D flow measure of mean pulmonary artery wedge pressure in pulmonary hypertension

    Article • Frontiers in Cardiovascular Medicine, August 2022, Frontiers

    Horst Olschewski

  51. Circulating microRNAs as molecular biomarkers for lung adenocarcinoma

    Article • Cancer Biomarkers, July 2022, IOS Press

    Horst Olschewski

  52. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension

    Article • Pulmonary Circulation, July 2022, Wiley

    Horst Olschewski

  53. Severe Pulmonary Hypertension in COPD

    Article • CHEST Journal, July 2022, Elsevier

    Horst Olschewski

  54. Lung vascular changes as biomarkers of severity in systemic sclerosis–associated interstitial lung disease

    Article • Rheumatology, June 2022, Oxford University Press (OUP)

    Horst Olschewski

  55. Automated vortical blood flow-based estimation of mean pulmonary arterial pressure from 4D flow MRI

    Article • Magnetic Resonance Imaging, May 2022, Elsevier

    Horst Olschewski

  56. Potassium Channels in the Transition from Fetal to the Neonatal Pulmonary Circulation

    Article • International Journal of Molecular Sciences, April 2022, MDPI AG

    Horst Olschewski

  57. Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022)

    Article • Wiener klinische Wochenschrift, April 2022, Springer Science + Business Media

    Horst Olschewski

  58. Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of systemic sclerosis-associated interstitial lung disease

    Article • European Respiratory Journal, March 2022, European Respiratory Society (ERS)

    Horst Olschewski

  59. Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review

    Article • European Respiratory Journal, March 2022, European Respiratory Society (ERS)

    Horst Olschewski

  60. Impairment of Inspiratory Muscle Function after COVID-19

    Article • Respiration, January 2022, Karger Publishers

    Horst Olschewski

  61. Revisiting the Large-Conductance Calcium-Activated Potassium (BKCa) Channels in the Pulmonary Circulation

    Article • Biomolecules, November 2021, MDPI AG

    Horst Olschewski

  62. PCK2 opposes mitochondrial respiration and maintains the redox balance in starved lung cancer cells

    Article • Free Radical Biology and Medicine, November 2021, Elsevier

    Horst Olschewski

  63. Monocytes and Macrophages Serve as Potent Prostaglandin D2 Sources during Acute, Non-Allergic Pulmonary Inflammation

    Article • International Journal of Molecular Sciences, October 2021, MDPI AG

    Horst Olschewski

  64. Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer

    Article • Wiener klinische Wochenschrift, September 2021, Springer Science + Business Media

    Horst Olschewski

  65. The definition of pulmonary hypertension: history, practical implications and current controversies

    Article • Breathe, September 2021, European Respiratory Society (ERS)

    Horst Olschewski

  66. RGS5 Determines Neutrophil Migration in the Acute Inflammatory Phase of Bleomycin-Induced Lung Injury

    Article • International Journal of Molecular Sciences, August 2021, MDPI AG

    Horst Olschewski

  67. Low oxygen levels decrease adaptive immune responses and ameliorate experimental asthma in mice

    Article • Allergy, August 2021, Wiley

    Horst Olschewski

  68. Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances

    Article • American Review of Respiratory Disease, June 2021, American Thoracic Society

    Horst Olschewski

  69. Elevated pulmonary vascular resistance predicts mortality in COPD patients

    Article • European Respiratory Journal, May 2021, European Respiratory Society (ERS)

    Horst Olschewski

  70. Dysbalance of ACE2 levels – a possible cause for severe COVID‐19 outcome in COPD

    Article • The Journal of Pathology Clinical Research, May 2021, Wiley

    Horst Olschewski

  71. Between inflammation and thrombosis: endothelial cells in COVID-19

    Article • European Respiratory Journal, May 2021, European Respiratory Society (ERS)

    Horst Olschewski

  72. Chronisch-obstruktive Lungenerkrankung 2021 – die richtige Therapie für den richtigen Patienten

    Article • Der Internist, April 2021, Springer Science + Business Media

    Horst Olschewski

  73. Impact of Smoking Behavior on Survival Following Allogeneic Hematopoietic Stem Cell Transplantation – Smoking Cessation Matters

    Article • Nicotine & Tobacco Research, April 2021, Oxford University Press (OUP)

    Horst Olschewski

  74. Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways

    Article • Journal of Cardiovascular Pharmacology and Therapeutics, April 2021, SAGE Publications

    Horst Olschewski

  75. The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease

    Article • Diagnostics, February 2021, MDPI AG

    Horst Olschewski

  76. Exercise Pulmonary Resistances Predict Long-Term Survival in Systemic Sclerosis

    Article • CHEST Journal, February 2021, Elsevier

    Horst Olschewski

  77. Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension

    Article • Circulation Genomic and Precision Medicine, February 2021, Wolters Kluwer Health

    Horst Olschewski

  78. Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case series

    Article • BMC Pulmonary Medicine, January 2021, Springer Science + Business Media

    Horst Olschewski

  79. Phospholipid dynamics in ex vivo lung cancer and normal lung explants

    Article • Experimental & Molecular Medicine, January 2021, Springer Science + Business Media

    Horst Olschewski

  80. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial

    Article • European Heart Journal, November 2020, Oxford University Press (OUP)

    Horst Olschewski

  81. Covid‑19 – was wir sicher wissen

    Article • Der Pneumologe, November 2020, Springer Science + Business Media

    Horst Olschewski

  82. Clinical-Pathological Conference Series from the Medical University of Graz

    Article • Wiener klinische Wochenschrift, October 2020, Springer Science + Business Media

    Horst Olschewski

  83. MR 4D flow-based mean pulmonary arterial pressure tracking in pulmonary hypertension

    Article • European Radiology, September 2020, Springer Science + Business Media

    Horst Olschewski

  84. TMEM16A Potentiation: Possible Drawbacks

    Article • American Review of Respiratory Disease, September 2020, American Thoracic Society

    Horst Olschewski

  85. Distribution and prognostic significance of gluconeogenesis and glycolysis in lung cancer

    Article • Molecular Oncology, September 2020, Wiley

    Horst Olschewski

  86. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study

    Article • The Lancet Respiratory Medicine, September 2020, Elsevier

    Horst Olschewski

  87. Masterplan 2025 der Österreichischen Gesellschaft für Pneumologie (ÖGP) – die erwartete Entwicklung und Versorgung respiratorischer Erkrankungen in Österreich

    Article • Wiener klinische Wochenschrift, September 2020, Springer Science + Business Media

    Horst Olschewski

  88. Endothelial Dysfunction Following Enhanced TMEM16A Activity in Human Pulmonary Arteries

    Article • Cells, August 2020, MDPI AG

    Horst Olschewski

  89. C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study

    Article • Cancers, August 2020, MDPI AG

    Horst Olschewski

  90. CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis

    Article • Respiratory Research, July 2020, Springer Science + Business Media

    Horst Olschewski

  91. Basement Membrane Remodeling Controls Endothelial Function in Idiopathic Pulmonary Arterial Hypertension

    Article • American Journal of Respiratory Cell and Molecular Biology, July 2020, American Thoracic Society

    Horst Olschewski

  92. Quality of Life and Limitations in Daily Life of Stable COPD Outpatients in a Real-World Setting in Austria – Results from the CLARA Project

    Article • International Journal of Chronic Obstructive Pulmonary Disease, July 2020, Taylor & Francis

    Horst Olschewski

  93. Multi-channel lung sound classification with convolutional recurrent neural networks

    Article • Computers in Biology and Medicine, July 2020, Elsevier

    Horst Olschewski

  94. Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9 May 2020)

    Article • Wiener klinische Wochenschrift, June 2020, Springer Science + Business Media

    Horst Olschewski

  95. No indication of insulin resistance in idiopathic pulmonary arterial hypertension with preserved physical activity

    Article • European Respiratory Journal, March 2020, European Respiratory Society (ERS)

    Horst Olschewski

  96. Pulmonary hypertension in chronic obstructive pulmonary disease

    Article • British Journal of Pharmacology, March 2020, Wiley

    Horst Olschewski

  97. Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension

    Article • American Review of Respiratory Disease, March 2020, American Thoracic Society

    Professor Allan Lawrie, Horst Olschewski

  98. Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue

    Article • Journal of Allergy and Clinical Immunology, March 2020, Elsevier

    Horst Olschewski

  99. MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2

    Article • Cancer Letters, January 2020, Elsevier

    Horst Olschewski

  100. Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations

    Article • Thoracic Cancer, December 2019, Wiley

    Horst Olschewski

  101. Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis

    Article • BMC Pulmonary Medicine, November 2019, Springer Science + Business Media

    Horst Olschewski

  102. Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease

    Article • JACC Heart Failure, October 2019, Elsevier

    Horst Olschewski

  103. Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis?

    Article • European Journal of Heart Failure, August 2019, Wiley

    Horst Olschewski

  104. Debating the new haemodynamic definition of pulmonary hypertension: much ado about nothing?

    Article • European Respiratory Journal, August 2019, European Respiratory Society (ERS)

    Horst Olschewski

  105. Gluconeogenesis in cancer cells – Repurposing of a starvation-induced metabolic pathway?

    Article • Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, August 2019, Elsevier

    Horst Olschewski

  106. Take your drug and climb Machu Picchu!

    Article • International Journal of Cardiology, August 2019, Elsevier

    Horst Olschewski

  107. IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis

    Article • European Respiratory Journal, July 2019, European Respiratory Society (ERS)

    Anna Birnhuber, Horst Olschewski

  108. Pulmonary and cardiac drugs: clinically relevant interactions

    Article • Herz, July 2019, Springer Science + Business Media

    Horst Olschewski

  109. Hämodynamische Definition der pulmonalen Hypertonie: Kommentar zu der vorgeschlagenen Änderung durch das 6th World Symposium on Pulmonary Hypertension

    Article • DMW - Deutsche Medizinische Wochenschrift, July 2019, Thieme Publishing Group

    Horst Olschewski

  110. Advanced interstitial lung fibrosis with emphysema and pulmonary hypertension with no evidence for interstitial lung disease on high resolution CT

    Article • Pulmonary Circulation, July 2019, Wiley

    Horst Olschewski

  111. Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI)

    Article • Pulmonary Circulation, July 2019, Wiley

    Horst Olschewski

  112. Disconnect between Fibrotic Response and Right Ventricular Dysfunction

    Article • American Review of Respiratory Disease, June 2019, American Thoracic Society

    Horst Olschewski

  113. Potential role of exercise echocardiography and right heart catheterization in the detection of early pulmonary vascular disease in patients with systemic sclerosis

    Article • Journal of Scleroderma and Related Disorders, May 2019, SAGE Publications

    Horst Olschewski

  114. Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic PAH

    Article • European Respiratory Journal, April 2019, European Respiratory Society (ERS)

    Horst Olschewski

  115. The pulmonary haemodynamics during exercise – research network (PEX-NET) ERS Clinical Research Collaboration: investigating the prognostic relevance of exercise haemodynamics

    Article • European Respiratory Journal, April 2019, European Respiratory Society (ERS)

    Horst Olschewski

  116. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis

    Article • The Lancet Respiratory Medicine, March 2019, Elsevier

    Professor Allan Lawrie, Horst Olschewski

  117. Quantitative CT‐derived vessel metrics in idiopathic pulmonary fibrosis: A structure–function study

    Article • Respirology, February 2019, Wiley

    Horst Olschewski

  118. Long non‐coding RNAs influence the transcriptome in pulmonary arterial hypertension: the role of PAXIP1‐AS1

    Article • The Journal of Pathology, January 2019, Wiley

    Horst Olschewski

  119. Pulmonary hypertension in chronic lung disease and hypoxia

    Article • European Respiratory Journal, January 2019, European Respiratory Society (ERS)

    Dr Steven D Nathan, Horst Olschewski

  120. Whole-Body Lung Function Test–Derived Outcome Predictors in Allogenic Stem Cell Transplantation

    Article • Biology of Blood and Marrow Transplantation, January 2019, Elsevier

    Horst Olschewski

  121. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension

    Article • European Respiratory Journal, December 2018, European Respiratory Society (ERS)

    Horst Olschewski

  122. Imatinib for right heart failure in COPD

    Article • Pulmonary Circulation, December 2018, Wiley

    Horst Olschewski

  123. Cologne consensus conference on pulmonary hypertension – Update 2018

    Article • International Journal of Cardiology, December 2018, Elsevier

    Horst Olschewski

  124. Should patients with pulmonary hypertension fly and climb?

    Article • International Journal of Cardiology, November 2018, Elsevier

    Horst Olschewski

  125. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?

    Article • American Review of Respiratory Disease, October 2018, American Thoracic Society

    Horst Olschewski

  126. Are anticoagulants still indicated in pulmonary arterial hypertension?

    Article • October 2018, SAGE Publications

    Horst Olschewski

  127. Clinical-Pathological Conference Series from the Medical University of Graz

    Article • Wiener klinische Wochenschrift, October 2018, Springer Science + Business Media

    Horst Olschewski

  128. Pulmonary hypertension in hypersensitivity pneumonitis.

    Article • September 2018, European Respiratory Society (ERS)

    Horst Olschewski

  129. Right ventricular tissue doppler echocardiography in pulmonary hypertension

    Article • September 2018, European Respiratory Society (ERS)

    Horst Olschewski

  130. Advancing into the details of pulmonary haemodynamics during exercise

    Article • European Respiratory Journal, September 2018, European Respiratory Society (ERS)

    Horst Olschewski

  131. Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis

    Article • European Respiratory Journal, August 2018, European Respiratory Society (ERS)

    Malgorzata Wygrecka, Horst Olschewski

  132. Right ventricular fibrosis and dysfunction: Actual concepts and common misconceptions

    Article • Matrix Biology, August 2018, Elsevier

    Horst Olschewski

  133. Crackle and Breathing Phase Detection in Lung Sounds with Deep Bidirectional Gated Recurrent Neural Networks

    Article • July 2018, Institute of Electrical & Electronics Engineers (IEEE)

    Horst Olschewski

  134. Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach

    Article • Frontiers in Physiology, June 2018, Frontiers

    Horst Olschewski

  135. The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells

    Article • Proceedings of the National Academy of Sciences, May 2018, Proceedings of the National Academy of Sciences

    Horst Olschewski

  136. Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension

    Article • Frontiers in Physiology, May 2018, Frontiers

    Horst Olschewski

  137. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension

    Article • Nature Communications, April 2018, Springer Science + Business Media

    Professor Allan Lawrie, Horst Olschewski

  138. Healthy Lung Vessel Morphology Derived From Thoracic Computed Tomography

    Article • Frontiers in Physiology, April 2018, Frontiers

    Horst Olschewski

  139. Resident cell lineages are preserved in pulmonary vascular remodeling

    Article • The Journal of Pathology, March 2018, Wiley

    Horst Olschewski

  140. Pulmonary capillary recruitment in exercise and pulmonary hypertension

    Article • European Respiratory Journal, March 2018, European Respiratory Society (ERS)

    Horst Olschewski

  141. Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality

    Article • American Review of Respiratory Disease, February 2018, American Thoracic Society

    Horst Olschewski

  142. Network Analysis to Risk Stratify Patients With Exercise IntoleranceNovelty and Significance

    Article • Circulation Research, February 2018, Wolters Kluwer Health

    Rudolf Oliveira, Horst Olschewski

  143. The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension

    Article • European Respiratory Journal, January 2018, European Respiratory Society (ERS)

    Horst Olschewski

  144. No erythropoietin-induced growth is observed in non-small cell lung cancer cells

    Article • International Journal of Oncology, December 2017, Spandidos Publications

    Horst Olschewski

  145. MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas

    Article • Oncotarget, December 2017, Impact Journals, LLC

    Horst Olschewski

  146. An official European Respiratory Society statement: pulmonary haemodynamics during exercise

    Article • European Respiratory Journal, November 2017, European Respiratory Society (ERS)

    Horst Olschewski

  147. Importance of kynurenine in pulmonary hypertension

    Article • AJP Lung Cellular and Molecular Physiology, November 2017, American Physiological Society

    Horst Olschewski

  148. Understanding exercise hemodynamics

    Article • Pulmonary Circulation, September 2017, SAGE Publications

    Horst Olschewski

  149. TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1α

    Article • Lung Cancer, September 2017, Elsevier

    Horst Olschewski

  150. Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study

    Article • European Respiratory Journal, July 2017, European Respiratory Society (ERS)

    Horst Olschewski

  151. Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on p22phox

    Article • European Respiratory Journal, July 2017, European Respiratory Society (ERS)

    Horst Olschewski

  152. The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension

    Article • Pulmonary Circulation, May 2017, SAGE Publications

    Horst Olschewski

  153. Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to Hypoxia

    Article • Frontiers in Physiology, February 2017, Frontiers

    Horst Olschewski

  154. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis

    Article • Heart, January 2017, BMJ

    Horst Olschewski

  155. Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension

    Article • PLOS One, December 2016, PLOS

    Horst Olschewski

  156. Automated integer programming based separation of arteries and veins from thoracic CT images

    Article • Medical Image Analysis, December 2016, Elsevier

    Horst Olschewski

  157. ESC-Leitlinie 2015: Diagnostik und Therapie der pulmonalen Hypertonie

    Article • DMW - Deutsche Medizinische Wochenschrift, November 2016, Thieme Publishing Group

    Horst Olschewski

  158. Pulmonale Hypertonie: Kölner Konsensus-Konferenz 2016

    Article • DMW - Deutsche Medizinische Wochenschrift, November 2016, Thieme Publishing Group

    Horst Olschewski

  159. Pulmonale Hypertonie bei Lungenkrankheiten: Empfehlungen der Kölner Konsensus-Konferenz 2016

    Article • DMW - Deutsche Medizinische Wochenschrift, October 2016, Thieme Publishing Group

    Horst Olschewski

  160. Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different?

    Article • September 2016, European Respiratory Society (ERS)

    Horst Olschewski

  161. Why We Should Care about the Mysteries of Pulmonary Hypertension

    Article • Pulmonary Circulation, September 2016, SAGE Publications

    Horst Olschewski

  162. Does exercise pulmonary hypertension exist?

    Article • Current Opinion in Pulmonary Medicine, September 2016, Wolters Kluwer Health

    Horst Olschewski

  163. Docosahexaenoic acid causes rapid pulmonary arterial relaxationviaKCa channel-mediated hyperpolarisation in pulmonary hypertension

    Article • European Respiratory Journal, August 2016, European Respiratory Society (ERS)

    Horst Olschewski

  164. Counter-clockwise vortical blood flow in the main pulmonary artery in a patient with patent ductus arteriosus with pulmonary arterial hypertension: a cardiac magnetic resonance imaging case report

    Article • BMC Medical Imaging, August 2016, Springer Science + Business Media

    Horst Olschewski

  165. Amitriptyline and carbamazepine utilize voltage-gated ion channel suppression to impair excitability of sensory dorsal horn neurons in thin tissue slice: An in vitro study

    Article • Neuroscience Research, August 2016, Elsevier

    Horst Olschewski

  166. Functional and molecular factors associated with TAPSE in hypoxic pulmonary hypertension

    Article • AJP Lung Cellular and Molecular Physiology, July 2016, American Physiological Society

    Horst Olschewski

  167. TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers

    Article • PLOS One, June 2016, PLOS

    Horst Olschewski

  168. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial

    Article • The Lancet Respiratory Medicine, June 2016, Elsevier

    Horst Olschewski

  169. Forschung in Österreich – das Ludwig Boltzmann Institut für Lungengefäßforschung

    Article • Pneumologie, May 2016, Thieme Publishing Group

    Horst Olschewski

  170. Survival in patients with borderline pulmonary arterial pressure

    Article • Pneumologie, May 2016, Thieme Publishing Group

    Horst Olschewski

  171. Prognostic relevance of differential blood count in pulmonary arterial hypertension

    Article • Pneumologie, May 2016, Thieme Publishing Group

    Horst Olschewski

  172. Native myocardial T1 mapping in pulmonary hypertension: correlations with cardiac function and hemodynamics

    Article • European Radiology, April 2016, Springer Science + Business Media

    Horst Olschewski

  173. Circulating endothelial progenitor cells are associated with PAH but they are heterogeneous

    Article • European Respiratory Journal, April 2016, European Respiratory Society (ERS)

    Horst Olschewski

  174. Pulmonary arterial pressure in patients with myelodysplastic syndromes

    Article • Leukemia & Lymphoma, April 2016, Taylor & Francis

    Horst Olschewski

  175. Pulmonal (arterielle) Hypertonie

    Article • Pneumologie, April 2016, Thieme Publishing Group

    Horst Olschewski

  176. Pulmonalembolie und direkte orale Antikoagulantien

    Article • Wiener Medizinische Wochenschrift, March 2016, Springer Science + Business Media

    Horst Olschewski

  177. Letter by Olschewski et al Regarding Article, “Upregulation of K 2P 3.1 K + Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation”

    Article • Circulation, March 2016, Wolters Kluwer Health

    Horst Olschewski

  178. Proposed new definition of exercise pulmonary hypertension decreases false-positive cases

    Article • European Respiratory Journal, January 2016, European Respiratory Society (ERS)

    Horst Olschewski

  179. Pulmonale Hypertonie

    Article • January 2016, Springer Science + Business Media

    Horst Olschewski

  180. Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertension　– Insights From the IBUKI and AIR Studies –

    Article • Circulation Journal, January 2016, Japanese Circulation Society

    Horst Olschewski

  181. Selexipag for the Treatment of Pulmonary Arterial Hypertension

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2015, New England Journal of Medicine (NEJM/MMS)

    Professor Olivier SITBON, Horst Olschewski

  182. Clinical Manifestations of Respiratory Bronchiolitis as an Incidental Finding in Surgical Lung Biopsies: A Retrospective Analysis of a Large Austrian Registry

    Article • Respiration, December 2015, Karger Publishers

    Horst Olschewski

  183. ESC-Leitlinien 2015 zur pulmonalen Hypertonie

    Article • Herz, December 2015, Springer Science + Business Media

    Horst Olschewski

  184. Sleep Related Breathing Disorders and Inflammation — The Missing Link? A Cohort Study Evaluating the Interaction of Inflammation and Sleep Related Breathing Disorders and Effects of Treatment

    Article • PLOS One, September 2015, PLOS

    Horst Olschewski

  185. Cardiopulmonary comorbidities are associated with hemodynamics in pulmonary arterial hypertension

    Article • September 2015, European Respiratory Society (ERS)

    Horst Olschewski

  186. The influence of erythropoietin on growth and survival in non-small cell lung cancer cell lines

    Article • September 2015, European Respiratory Society (ERS)

    Horst Olschewski

  187. Pressure Overload Creates Right Ventricular Diastolic Dysfunction in a Mouse Model: Assessment by Echocardiography

    Article • Journal of the American Society of Echocardiography, July 2015, Elsevier

    Horst Olschewski

  188. Borderline pulmonary pressures in scleroderma - a ‘pre-pulmonary arterial hypertension’ condition?

    Article • Arthritis Research & Therapy, May 2015, Springer Science + Business Media

    Horst Olschewski

  189. Compartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients

    Article • AJP Lung Cellular and Molecular Physiology, May 2015, American Physiological Society

    Horst Olschewski

  190. Impact of cardiopulmonary comorbidities on pulmonary hemodynamics

    Article • Pneumologie, May 2015, Thieme Publishing Group

    Horst Olschewski

  191. Blood Flow Vortices along the Main Pulmonary Artery Measured with MR Imaging for Diagnosis of Pulmonary Hypertension

    Article • Radiology, April 2015, Radiological Society of North America (RSNA)

    Horst Olschewski

  192. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization

    Article • Molecular Cancer, January 2015, Springer Science + Business Media

    Horst Olschewski

  193. Imatinib for Pulmonary Arterial Hypertension - Wonder Drug or Killer Drug?

    Article • Respiration, January 2015, Karger Publishers

    Horst Olschewski

  194. Allgemeine Therapie der pulmonal arteriellen Hypertonie

    Article • DMW - Deutsche Medizinische Wochenschrift, December 2014, Thieme Publishing Group

    Horst Olschewski

  195. Einsatz von Imatinib bei Patienten mit Pulmonal Arterieller Hypertonie

    Article • DMW - Deutsche Medizinische Wochenschrift, December 2014, Thieme Publishing Group

    Horst Olschewski

  196. Moderne bildgebende Verfahren im Management der pulmonalen Hypertonie

    Article • DMW - Deutsche Medizinische Wochenschrift, December 2014, Thieme Publishing Group

    Horst Olschewski

  197. Gezielte Therapie der pulmonal arteriellen Hypertonie (PAH)

    Article • DMW - Deutsche Medizinische Wochenschrift, December 2014, Thieme Publishing Group

    Horst Olschewski

  198. Ion channels and transporters as therapeutic targets in the pulmonary circulation

    Article • Pharmacology & Therapeutics, December 2014, Elsevier

    Horst Olschewski

  199. Characterization of Patients With Borderline Pulmonary Arterial Pressure

    Article • CHEST Journal, December 2014, Elsevier

    Horst Olschewski

  200. Reply: Reading of Pulmonary Artery Pressure Tracings: The Best Compromise of Accuracy and Clinical Pertinence

    Article • American Review of Respiratory Disease, November 2014, American Thoracic Society

    Horst Olschewski

  201. Diagnostik der pulmonalen Hypertonie – Neues nach dem 5. Weltkongress

    Article • Pneumologie, November 2014, Thieme Publishing Group

    Horst Olschewski

  202. Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics

    Article • European Journal of Pharmaceutics and Biopharmaceutics, November 2014, Elsevier

    Horst Olschewski

  203. Gluconeogenesis in cancer: Door wide open

    Article • Proceedings of the National Academy of Sciences, September 2014, Proceedings of the National Academy of Sciences

    Horst Olschewski

  204. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients

    Article • European Respiratory Journal, July 2014, European Respiratory Society (ERS)

    Horst Olschewski

  205. Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries

    Article • International Journal of Nanomedicine, July 2014, Taylor & Francis

    Professor Ruth Prassl, Dr Nagaraj chandran, Horst Olschewski

  206. Distinct Differences in Gene Expression Patterns in Pulmonary Arteries of Patients with Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis with Pulmonary Hypertension

    Article • American Review of Respiratory Disease, July 2014, American Thoracic Society

    Horst Olschewski

  207. READING PULMONARY VASCULAR PRESSURE TRACINGS How to handle the problems of zero leveling and respiratory swings

    Article • American Review of Respiratory Disease, May 2014, American Thoracic Society

    Horst Olschewski

  208. Complete resolution of idiopathic pulmonary arterial hypertension following chemotherapy

    Article • European Respiratory Journal, April 2014, European Respiratory Society (ERS)

    Horst Olschewski

  209. Kurzatmiger Patient — nicht immer ist er nur untrainiert

    Article • MMW - Fortschritte der Medizin, April 2014, Springer Science + Business Media

    Horst Olschewski

  210. PCK2 activation mediates an adaptive response to glucose depletion in lung cancer

    Article • Oncogene, March 2014, Springer Science + Business Media

    Horst Olschewski

  211. Meprinβ, a novel mediator of vascular remodelling underlying pulmonary hypertension

    Article • The Journal of Pathology, January 2014, Wiley

    Horst Olschewski

  212. Quantification of Tortuosity and Fractal Dimension of the Lung Vessels in Pulmonary Hypertension Patients

    Article • PLOS One, January 2014, PLOS

    Horst Olschewski

  213. Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model – role of tumor stroma cells

    Article • BMC Cancer, January 2014, Springer Science + Business Media

    Horst Olschewski

  214. Changes in Right Ventricular Function Measured by Cardiac Magnetic Resonance Imaging in Patients Receiving Pulmonary Arterial Hypertension–Targeted Therapy

    Article • Circulation Cardiovascular Imaging, January 2014, Wolters Kluwer Health

    Horst Olschewski

  215. Evaluation of Elevated Mean Pulmonary Arterial Pressure Based on Magnetic Resonance 4D Velocity Mapping: Comparison of Visualization Techniques

    Article • PLOS One, December 2013, PLOS

    Horst Olschewski

  216. Was ist pulmonale Hypertonie?

    Article • Pneumologie, December 2013, Thieme Publishing Group

    Horst Olschewski

  217. Non-invasive determination of pulmonary hypertension with dynamic contrast-enhanced computed tomography: a pilot study

    Article • European Radiology, December 2013, Springer Science + Business Media

    Horst Olschewski

  218. Updated Clinical Classification of Pulmonary Hypertension

    Article • Journal of the American College of Cardiology, December 2013, Elsevier

    Professor Rogerio Souza, Horst Olschewski

  219. Pulmonary arterial hypertension

    Article • December 2013, European Respiratory Society (ERS)

    Horst Olschewski

  220. Assessment and Prognostic Relevance of Right Ventricular Contractile Reserve in Patients With Severe Pulmonary Hypertension

    Article • Circulation, October 2013, Wolters Kluwer Health

    Horst Olschewski

  221. Docosahexaenoic acid (DHA)-induced heme oxygenase-1 attenuates cytotoxic effects of DHA in vascular smooth muscle cells

    Article • Atherosclerosis, October 2013, Elsevier

    Horst Olschewski

  222. PL-7 Positive Antisynthetase Syndrome and Pulmonary Hypertension

    Article • The Journal of Rheumatology, October 2013, The Journal of Rheumatology

    Horst Olschewski

  223. Determination of cardiac output with dynamic contrast-enhanced computed tomography

    Article • The International Journal of Cardiovascular Imaging, August 2013, Springer Science + Business Media

    Horst Olschewski

  224. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, July 2013, New England Journal of Medicine (NEJM/MMS)

    Horst Olschewski

  225. Riociguat for the Treatment of Pulmonary Arterial Hypertension

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, July 2013, New England Journal of Medicine (NEJM/MMS)

    Horst Olschewski, Professor Zhi-Cheng JING

  226. Pulmonary Hypertension

    Article • July 2013, Springer Science + Business Media

    Horst Olschewski

  227. Biomarkers in Pulmonary Hypertension

    Article • CHEST Journal, July 2013, Elsevier

    Horst Olschewski

  228. A 57-Year-Old Woman With Obesity, Respiratory Insufficiency, and Slowed Mental State

    Article • CHEST Journal, July 2013, Elsevier

    Horst Olschewski

  229. Die frühe Diagnose und Therapie der pulmonalen Hypertonie - Aspekte einer Vision

    Article • Pneumologie, June 2013, Thieme Publishing Group

    Horst Olschewski

  230. Zero reference level for right heart catheterisation

    Article • European Respiratory Journal, June 2013, European Respiratory Society (ERS)

    Horst Olschewski

  231. Double-Stranded RNA Attenuates the Barrier Function of Human Pulmonary Artery Endothelial Cells

    Article • PLOS One, June 2013, PLOS

    Horst Olschewski

  232. Stellungnahme der Österreichischen Röntgengesellschaft und der Österreichischen Gesellschaft für Pneumologie

    Article • Wiener klinische Wochenschrift, May 2013, Springer Science + Business Media

    Dr Helmut Prosch, Dr sylvia hartl, Horst Olschewski

  233. Loss of ABCG2 leads to right ventricular diastolic dysfunction in pulmonary hypertension

    Article • Pneumologie, May 2013, Thieme Publishing Group

    Horst Olschewski

  234. Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension

    Article • CHEST Journal, February 2013, Elsevier

    Horst Olschewski

  235. Prostacyclins

    Article • January 2013, Springer Science + Business Media

    Horst Olschewski

  236. Prostacyclins

    Article • January 2013, Springer Science + Business Media

    Horst Olschewski

  237. Exercise in Pulmonary Hypertension

    Article • Advances in Pulmonary Hypertension, December 2012, Pulmonary Hypertension Association

    Horst Olschewski

  238. HbA1c in pulmonary arterial hypertension: A marker of prognostic relevance?

    Article • The Journal of Heart and Lung Transplantation, October 2012, Elsevier

    Horst Olschewski

  239. Pulmonale Hypertonie

    Article • DMW - Deutsche Medizinische Wochenschrift, September 2012, Thieme Publishing Group

    Horst Olschewski

  240. Angiostatic Factors in the Pulmonary Endarterectomy Material from Chronic Thromboembolic Pulmonary Hypertension Patients Cause Endothelial Dysfunction

    Article • PLOS One, August 2012, PLOS

    Horst Olschewski

  241. Docosahexaenoic acid-induced unfolded protein response, cell cycle arrest, and apoptosis in vascular smooth muscle cells are triggered by Ca2+-dependent induction of oxidative stress

    Article • Free Radical Biology and Medicine, May 2012, Elsevier

    Horst Olschewski

  242. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries

    Article • European Respiratory Journal, April 2012, European Respiratory Society (ERS)

    Horst Olschewski

  243. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure

    Article • Arthritis & Rheumatism, March 2012, Wiley

    Horst Olschewski

  244. Peroxisome Proliferator–Activated Receptor–β/δ, the Acute Signaling Factor in Prostacyclin-Induced Pulmonary Vasodilation

    Article • American Journal of Respiratory Cell and Molecular Biology, March 2012, American Thoracic Society

    Horst Olschewski

  245. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension

    Article • The Journal of Heart and Lung Transplantation, December 2011, Elsevier

    Horst Olschewski

  246. Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011

    Article • International Journal of Cardiology, December 2011, Elsevier

    Horst Olschewski

  247. Rechtsherzkatheter-Untersuchung bei pulmonaler Hypertonie

    Article • DMW - Deutsche Medizinische Wochenschrift, December 2011, Thieme Publishing Group

    Horst Olschewski

  248. Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations

    Article • December 2011, Springer Science + Business Media

    Horst Olschewski

  249. Regulation der Kaliumkanäle in humanen pulmonal-arteriellen glatten Muskelzellen

    Article • Pneumologie, November 2011, Thieme Publishing Group

    Horst Olschewski

  250. Pulmonary vascular resistances during exercise in normal subjects: a systematic review

    Article • European Respiratory Journal, September 2011, European Respiratory Society (ERS)

    Horst Olschewski

  251. Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells

    Article • Cancer Letters, September 2011, Elsevier

    Horst Olschewski

  252. Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients

    Article • European Respiratory Journal, July 2011, European Respiratory Society (ERS)

    Horst Olschewski

  253. Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension

    Article • Respiration, January 2011, Karger Publishers

    Horst Olschewski

  254. Prostacyclin and Prostaglandins

    Article • December 2010, Springer Science + Business Media

    Horst Olschewski

  255. Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy

    Article • American Review of Respiratory Disease, November 2010, American Thoracic Society

    Horst Olschewski

  256. Therapie der pulmonal arteriellen Hypertonie (PAH)

    Article • DMW - Deutsche Medizinische Wochenschrift, September 2010, Thieme Publishing Group

    Horst Olschewski

  257. Assessment of Pulmonary Arterial Pressure During Exercise in Collagen Vascular Disease

    Article • CHEST Journal, August 2010, Elsevier

    Horst Olschewski

  258. Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension

    Article • Journal of the American College of Cardiology, May 2010, Elsevier

    Horst Olschewski

  259. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension

    Article • Respiratory Medicine, May 2010, Elsevier

    Horst Olschewski

  260. Intimal Sarcoma of the Pulmonary Valve

    Article • The Annals of Thoracic Surgery, April 2010, Elsevier

    Horst Olschewski

  261. Portopulmonary hypertension: short review

    Article • European Journal of Gastroenterology & Hepatology, April 2010, Wolters Kluwer Health

    Horst Olschewski

  262. The effect of terbutaline on the absorption of pulmonary administered insulin in subjects with asthma

    Article • British Journal of Clinical Pharmacology, March 2010, Wiley

    Horst Olschewski

  263. Borderline Pulmonary Arterial Pressure Is Associated with Decreased Exercise Capacity in Scleroderma

    Article • American Review of Respiratory Disease, November 2009, American Thoracic Society

    Horst Olschewski

  264. Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension

    Article • Journal of the American College of Cardiology, November 2009, Elsevier

    Horst Olschewski

  265. Noninvasive detection of early pulmonary vascular dysfunction in scleroderma

    Article • Respiratory Medicine, November 2009, Elsevier

    Horst Olschewski

  266. Endothelin-1 Inhibits Background Two-Pore Domain Channel TASK-1 in Primary Human Pulmonary Artery Smooth Muscle Cells

    Article • American Journal of Respiratory Cell and Molecular Biology, October 2009, American Thoracic Society

    Horst Olschewski

  267. Bildgebende Verfahren in Diagnostik und Verlaufskontrolle der pulmonalen arteriellen Hypertonie

    Article • DMW - Deutsche Medizinische Wochenschrift, August 2009, Thieme Publishing Group

    Horst Olschewski

  268. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy

    Article • Lung Cancer, July 2009, Elsevier

    Horst Olschewski

  269. Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension

    Article • Journal of the American College of Cardiology, June 2009, Elsevier

    Professor Rogerio Souza, Horst Olschewski

  270. Diagnosis and Assessment of Pulmonary Arterial Hypertension

    Article • Journal of the American College of Cardiology, June 2009, Elsevier

    Horst Olschewski

  271. Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension

    Article • Circulation, April 2009, Wolters Kluwer Health

    Horst Olschewski

  272. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review

    Article • European Respiratory Journal, March 2009, European Respiratory Society (ERS)

    Horst Olschewski

  273. Inhaled iloprost for the treatment of pulmonary hypertension

    Article • European Respiratory Review, March 2009, European Respiratory Society (ERS)

    Horst Olschewski

  274. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension

    Article • Pulmonary Pharmacology & Therapeutics, February 2009, Elsevier

    Horst Olschewski

  275. Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities

    Article • CHEST Journal, January 2009, Elsevier

    Horst Olschewski

  276. A 55-year-old craftsman with dyspnea and clubbing: a case report

    Article • Cases Journal, January 2009, Springer Science + Business Media

    Horst Olschewski

  277. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension

    Article • Pulmonary Pharmacology & Therapeutics, October 2008, Elsevier

    Horst Olschewski

  278. Dana Point: Was ist neu in der Diagnostik der Pulmonalen Hypertonie?

    Article • DMW - Deutsche Medizinische Wochenschrift, September 2008, Thieme Publishing Group

    Horst Olschewski

  279. Magnetic Resonance–Derived 3-Dimensional Blood Flow Patterns in the Main Pulmonary Artery as a Marker of Pulmonary Hypertension and a Measure of Elevated Mean Pulmonary Arterial Pressure

    Article • Circulation Cardiovascular Imaging, July 2008, Wolters Kluwer Health

    Horst Olschewski

  280. Oral and IntestinalCandidaColonization in Patients Undergoing Hematopoietic Stem‐Cell Transplantation

    Article • The Journal of Infectious Diseases, July 2008, Oxford University Press (OUP)

    Horst Olschewski

  281. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

    Article • Circulation, June 2008, Wolters Kluwer Health

    Horst Olschewski

  282. Prostacyclin therapies for the treatment of pulmonary arterial hypertension

    Article • European Respiratory Journal, April 2008, European Respiratory Society (ERS)

    Horst Olschewski

  283. The Emerging Role of Magnetic Resonance Imaging in the Diagnosis and Management of Pulmonary Hypertension

    Article • Respiration, January 2008, Karger Publishers

    Horst Olschewski

  284. Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function

    Article • Respiratory Physiology & Neurobiology, November 2007, Elsevier

    Horst Olschewski

  285. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension

    Article • European Respiratory Journal, November 2007, European Respiratory Society (ERS)

    Horst Olschewski

  286. Pulmonary Histoplasmosis in Three Austrian Travelers After a Journey to Mexico

    Article • Infection, September 2007, Springer Science + Business Media

    Horst Olschewski

  287. Highlights der Pulmonalen Hypertonie-Literatur

    Article • Pneumologie, July 2007, Thieme Publishing Group

    Horst Olschewski

  288. Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes

    Article • British Journal of Pharmacology, July 2007, Wiley

    Horst Olschewski

  289. Delayed Processing of Blood Samples Influences Time to Positivity of Blood Cultures and Results of Gram Stain-Acridine Orange Leukocyte Cytospin Test

    Article • Journal of Clinical Microbiology, May 2007, ASM Journals

    Horst Olschewski

  290. Aspergillus oryzae Peritonitis in CAPD: Case Report and Review of the Literature

    Article • American Journal of Kidney Diseases, May 2007, Elsevier

    Horst Olschewski

  291. Diagnostik und Therapie der chronischen pulmonalen Hypertonie

    Article • Clinical Research in Cardiology, May 2007, Springer Science + Business Media

    Horst Olschewski

  292. Effect of Inhaled Iloprost during Off-Medication Time in Patients with Pulmonary Arterial Hypertension

    Article • Respiration, January 2007, Karger Publishers

    Horst Olschewski

  293. Diagnostik und Therapie der chronischen pulmonalen Hypertonie

    Article • Pneumologie, December 2006, Thieme Publishing Group

    Horst Olschewski

  294. Derzeitige Empfehlungen zur Diagnostik und Therapie der pulmonalen Hypertonie

    Article • DMW - Deutsche Medizinische Wochenschrift, December 2006, Thieme Publishing Group

    Horst Olschewski

  295. Therapie der pulmonalarteriellen Hypertonie: Prostazyklin-Analoga

    Article • DMW - Deutsche Medizinische Wochenschrift, December 2006, Thieme Publishing Group

    Horst Olschewski

  296. Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension

    Article • Circulation, October 2006, Wolters Kluwer Health

    Horst Olschewski

  297. Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension

    Article • Journal of the American College of Cardiology, October 2006, Elsevier

    Horst Olschewski

  298. Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension

    Article • Journal of the American College of Cardiology, October 2006, Elsevier

    Horst Olschewski

  299. Stellenwert der Lyse bei akuter Lungenembolie

    Article • Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie, October 2006, Thieme Publishing Group

    Horst Olschewski

  300. Sildenafil treatment for portopulmonary hypertension

    Article • European Respiratory Journal, June 2006, European Respiratory Society (ERS)

    Horst Olschewski

  301. Impact of TASK-1 in Human Pulmonary Artery Smooth Muscle Cells

    Article • Circulation Research, April 2006, Wolters Kluwer Health

    Horst Olschewski

  302. Pulmonale Hypertonie: Die Zukunft hat begonnen

    Article • Medizinische Klinik, April 2006, Springer Science + Business Media

    Horst Olschewski

  303. Mutations of the TGF-β type II receptorBMPR2 in pulmonary arterial hypertension

    Article • Human Mutation, February 2006, Wiley

    Professor Olivier SITBON, Horst Olschewski

  304. Inhaled Treprostinil for Treatment of Chronic Pulmonary Arterial Hypertension

    Article • Annals of Internal Medicine, January 2006, American College of Physicians

    Horst Olschewski

  305. Diagnosis and treatment of pulmonary hypertonia

    Article • DMW - Deutsche Medizinische Wochenschrift, January 2006, Thieme Publishing Group

    Horst Olschewski

  306. Article • Orphanet Journal of Rare Diseases, January 2006, Springer Science + Business Media

    Horst Olschewski

  307. Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension

    Article • Cerebrovascular Diseases, January 2006, Karger Publishers

    Horst Olschewski

  308. Enhanced Hypoxic Pulmonary Vasoconstriction in Families of Adults or Children With Idiopathic Pulmonary Arterial Hypertension

    Article • CHEST Journal, December 2005, Elsevier

    Horst Olschewski

  309. Serotonin Transporter Gene Polymorphism in a Cohort of German Patients With Idiopathic Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension

    Article • CHEST Journal, December 2005, Elsevier

    Horst Olschewski

  310. Ketamine impairs excitability in superficial dorsal horn neurones by blocking sodium and voltage-gated potassium currents

    Article • British Journal of Pharmacology, November 2005, Wiley

    Horst Olschewski

  311. Ambrisentan Therapy for Pulmonary Arterial Hypertension

    Article • Journal of the American College of Cardiology, August 2005, Elsevier

    Horst Olschewski

  312. Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la hipertensión arterial pulmonar

    Article • Revista Española de Cardiología, May 2005, Elsevier

    Horst Olschewski

  313. Medikament�se Therapie der pulmonalen Hypertonie

    Article • Der Internist, March 2005, Springer Science + Business Media

    Horst Olschewski

  314. Article • European Heart Journal, December 2004, European Society of Cardiology

    Horst Olschewski

  315. Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension

    Article • Journal of Medical Genetics, December 2004, BMJ

    Horst Olschewski

  316. Novel case of dup(3q) syndrome due to a de novo interstitial duplication 3q24‐q26.31 with minimal overlap to the dup(3q) critical region

    Article • American Journal of Medical Genetics Part A, November 2004, Wiley

    Horst Olschewski

  317. Vasodilators in right heart failure - pro

    Article • DMW - Deutsche Medizinische Wochenschrift, November 2004, Thieme Publishing Group

    Horst Olschewski

  318. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertensionA randomized prospective study

    Article • Journal of the American College of Cardiology, October 2004, Elsevier

    Horst Olschewski

  319. Sildenafil Increased Exercise Capacity during Hypoxia at Low Altitudes and at Mount Everest Base Camp

    Article • Annals of Internal Medicine, August 2004, American College of Physicians

    Horst Olschewski

  320. Diagnosis and differential assessment of pulmonary arterial hypertension

    Article • Journal of the American College of Cardiology, June 2004, Elsevier

    Professor Olivier SITBON, Horst Olschewski

  321. Prostanoid therapy for pulmonary arterial hypertension

    Article • Journal of the American College of Cardiology, June 2004, Elsevier

    Professor Olivier SITBON, Horst Olschewski

  322. Prostacyclin and its analogues in the treatment of pulmonary hypertension

    Article • Pharmacology & Therapeutics, May 2004, Elsevier

    Horst Olschewski

  323. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV‐related severe pulmonary hypertension

    Article • European Respiratory Journal, February 2004, European Respiratory Society (ERS)

    Horst Olschewski

  324. Reversal of Nocturnal Periodic Breathing in Primary Pulmonary Hypertension After Lung Transplantation

    Article • CHEST Journal, January 2004, Elsevier

    Horst Olschewski

  325. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia

    Article • Journal of Medical Genetics, December 2003, BMJ

    Horst Olschewski

  326. Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension

    Article • CHEST Journal, October 2003, Elsevier

    Horst Olschewski

  327. Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure

    Article • European Respiratory Journal, August 2003, European Respiratory Society (ERS)

    Horst Olschewski

  328. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

    Article • Journal of the American College of Cardiology, July 2003, Elsevier

    Horst Olschewski

  329. Primary pulmonary hypertension may be a heterogeneous disease with a second locus on chromosome 2q31

    Article • Journal of the American College of Cardiology, June 2003, Elsevier

    Horst Olschewski

  330. Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension

    Article • American Review of Respiratory Disease, April 2003, American Thoracic Society

    Horst Olschewski

  331. Increased neutrophil mediator release in patients with pulmonary hypertension – suppression by inhaled iloprost

    Article • Thrombosis and Haemostasis, January 2003, Thieme Publishing Group

    Horst Olschewski

  332. Pulmonaler Hochdruck

    Article • Der Internist, December 2002, Springer Science + Business Media

    Horst Olschewski

  333. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension

    Article • Critical Care Medicine, November 2002, Wolters Kluwer Health

    Horst Olschewski

  334. Sildenafil zur Therapie der schweren pulmonalen Hypertonie und des beginnenden Rechtsherzversagens

    Article • Pneumologie, November 2002, Thieme Publishing Group

    Horst Olschewski

  335. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

    Article • The Lancet, September 2002, Elsevier

    Horst Olschewski

  336. Inhaled Iloprost for Severe Pulmonary Hypertension

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2002, New England Journal of Medicine (NEJM/MMS)

    Professor Olivier SITBON, Horst Olschewski

  337. Peripheral airway obstruction in primary pulmonary hypertension

    Article • Thorax, June 2002, BMJ

    Horst Olschewski

  338. Aerosolized Vasodilators in Pulmonary Hypertension

    Article • Journal of Aerosol Medicine, June 2002, Mary Ann Liebert Inc

    Horst Olschewski

  339. Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension

    Article • Annals of Internal Medicine, April 2002, American College of Physicians

    Horst Olschewski

  340. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: respondersversusnonresponders

    Article • European Respiratory Journal, April 2002, European Respiratory Society (ERS)

    Horst Olschewski

  341. Nocturnal periodic breathing in primary pulmonary hypertension

    Article • European Respiratory Journal, April 2002, European Respiratory Society (ERS)

    Horst Olschewski

  342. Outcome after Cardiopulmonary Resuscitation in Patients with Pulmonary Arterial Hypertension

    Article • American Review of Respiratory Disease, February 2002, American Thoracic Society

    Horst Olschewski

  343. Cellular pathophysiology and therapy of pulmonary hypertension

    Article • Journal of Laboratory and Clinical Medicine, December 2001, Elsevier

    Horst Olschewski

  344. Recommendations for the Choice of Inhalatory Systems for Drug Prescription

    Article • Pneumologie, December 2001, Thieme Publishing Group

    Horst Olschewski

  345. Physiologic basis for the treatment of pulmonary hypertension

    Article • Journal of Laboratory and Clinical Medicine, November 2001, Elsevier

    Horst Olschewski

  346. Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension

    Article • Journal of the American College of Cardiology, October 2001, Elsevier

    Horst Olschewski

  347. Basic Electrical Properties ofIn situEndothelial Cells of Small Pulmonary Arteries during Postnatal Development

    Article • American Journal of Respiratory Cell and Molecular Biology, September 2001, American Thoracic Society

    Horst Olschewski

  348. Obstructive Sleep Apnoea and Cardiovascular Diseases - Hypothesis of Pathophysiological Interlinks

    Article • Pneumologie, June 2001, Thieme Publishing Group

    Horst Olschewski

  349. Does the tuberous sclerosis complex include clivus chordoma? A case report

    Article • European Journal of Pediatrics, January 2001, Springer Science + Business Media

    Horst Olschewski

  350. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension

    Article • European Respiratory Journal, January 2001, European Respiratory Society (ERS)

    Horst Olschewski

  351. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy

    Article • Thorax, December 2000, BMJ

    Horst Olschewski

  352. Diagnostik der akuten Lungenembolie - Empfehlungen der Deutsche Gesellschaft für Pneumologie -

    Article • Pneumologie, December 2000, Thieme Publishing Group

    Horst Olschewski

  353. Prävalenz von Schlaganfall und transitorischer ischämischer Attacke (TIA) bei obstruktiver Schlaf-Apnoe: eine retrospektive Erhebung an 187 konsekutiven Patienten1

    Article • Pneumologie, December 2000, Thieme Publishing Group

    Horst Olschewski

  354. Abnormal Pulmonary Artery Pressure Response in Asymptomatic Carriers of Primary Pulmonary Hypertension Gene

    Article • Circulation, September 2000, Wolters Kluwer Health

    Horst Olschewski

  355. Enhanced Release of Superoxide from Polymorphonuclear Neutrophils in Obstructive Sleep Apnea

    Article • American Review of Respiratory Disease, August 2000, American Thoracic Society

    Horst Olschewski

  356. Inhalative Strategien zur Verbesserung der pulmonalen Hämodynamik und des Gasaustausches bei Sepsis und schwerer pulmonaler Hypertonie

    Article • Zeitschrift für Kardiologie, June 2000, Springer Science + Business Media

    Horst Olschewski

  357. Behandlung der Pulmonal Arteriellen Hypertonie

    Article • Pneumologie, June 2000, Thieme Publishing Group

    Horst Olschewski

  358. Screen–printed enzyme sensors for l-lysine determination

    Article • Enzyme and Microbial Technology, April 2000, Elsevier

    Horst Olschewski

  359. Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial

    Article • Annals of Internal Medicine, March 2000, American College of Physicians

    Horst Olschewski

  360. Inhaliertes Prostazyklin und Iloprost bei schwerer sekundärer pulmonaler Hypertonie durch Lungenfibrose1

    Article • Pneumologie, March 2000, Thieme Publishing Group

    Horst Olschewski

  361. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

    Article • Journal of the American College of Cardiology, January 2000, Elsevier

    Horst Olschewski

  362. Severe Microcirculatory Abnormalities Elicited byE. coliHemolysin in the Rabbit Ileum Mucosa

    Article • American Review of Respiratory Disease, October 1999, American Thoracic Society

    Horst Olschewski

  363. Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis

    Article • American Review of Respiratory Disease, August 1999, American Thoracic Society

    Horst Olschewski

  364. Physiologie und Pathophysiologie der pulmonalen Zirkulation

    Article • Der Internist, June 1999, Springer Science + Business Media

    Horst Olschewski

  365. Vasotrope Therapie und Beatmung bei pulmonaler Hypertonie

    Article • Der Internist, June 1999, Springer Science + Business Media

    Horst Olschewski

  366. Effect of bupivacaine on ATP-dependent potassium channels in rat cardiomyocytes

    Article • British Journal of Anaesthesia, March 1999, Elsevier

    Horst Olschewski

  367. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost

    Article • Intensive Care Medicine, June 1998, Springer Science + Business Media

    Horst Olschewski

  368. Abnormalities of Gastric Mucosal Oxygenation in Septic Shock

    Article • American Review of Respiratory Disease, May 1998, American Thoracic Society

    Horst Olschewski

  369. NO und alternative inhalative Therapieansätze bei pulmonaler Hypertonie

    Article • Der Internist, May 1997, Springer Science + Business Media

    Horst Olschewski

  370. Advantage of buffered solutions or automated capnometry in air-filled balloons for use in gastric tonometry

    Article • Intensive Care Medicine, April 1997, Springer Science + Business Media

    Horst Olschewski

  371. Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension

    Article • Annals of Internal Medicine, May 1996, American College of Physicians

    Horst Olschewski

  372. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome.

    Article • American Review of Respiratory Disease, March 1996, American Thoracic Society

    Horst Olschewski

  373. ATP-Dependent Potassium Channel in Rat Cardiomyocytes Is Blocked by Lidocaine

    Article • Circulation, February 1996, Wolters Kluwer Health

    Horst Olschewski

  374. Temperature effects on ventilatory rate, heart rate, and preferred pedal rate during cycle ergometry

    Article • Journal of Applied Physiology, September 1995, American Physiological Society

    Horst Olschewski

  375. Cardiac responses to the Valsalva manoeuvre in different body positions

    Article • European Journal of Applied Physiology and Occupational Physiology, September 1990, Springer Science + Business Media

    Horst Olschewski

  376. Thermoregulatory, cardiovascular, and muscular factors related to exercise after precooling

    Article • Journal of Applied Physiology, February 1988, American Physiological Society

    Horst Olschewski

  377. Body temperature related factors diminishing the drive to exercise

    Article • Canadian Journal of Physiology and Pharmacology, June 1987, Canadian Science Publishing

    Horst Olschewski

  378. Pulmonary Hypertension

    Article • Wiley

    Horst Olschewski